Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
1: Liothyronine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Liothyronine Sodium Tablets, 50 mcg |
| 2 | ACTIVE_COMPARATOR | Cytomel® Tablets, 50 mcg |
| Name | Type | Description |
|---|---|---|
| 1: Liothyronine Sodium Tablets | DRUG | Liothyronine Sodium Tablets, 50 mcg 2 x 50 mcg, single-dose, fasting |
| 2: Cytomel® Tablets | DRUG | Cytomel® Tablets, 50 mcg 2 x 50 mcg, single-dose, fasting |
Inclusion Criteria: * healthy males and/or non-pregnant, non-lactating females, 18 years and older * able to swallow medication Exclusion Criteria: * institutionalized subjects * history of any significant disease * use of any prescription or OTC medications within 14 days prior to start of study...
Liothyronine is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with one completed trial evaluating its pharmacokinetic profile. The drug is being developed by Viatris Inc. and is not yet approved for any indication.
Liothyronine is being developed by Viatris Inc., a pharmaceutical company traded on the NASDAQ under the ticker symbol VTRS. The company is conducting clinical research on this small molecule drug, which is currently in Phase 1 development.
Liothyronine is in Phase 1 clinical development. One Phase 1 trial has been completed, involving 31 participants. The drug is investigational and has not been approved by regulatory authorities. It is being studied in healthy volunteers to assess its pharmacokinetic properties.
Liothyronine has one completed clinical trial registered under NCT00978055, titled "Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)." This Phase 1 study enrolled 31 healthy volunteers in the United States and was active-controlled, though not double-blinded.
Liothyronine is being studied as a generic alternative to Cytomel, a brand-name liothyronine sodium tablet. The clinical trial NCT00978055 compared liothyronine sodium tablets (50 mcg) to Cytomel tablets (50 mcg) in healthy volunteers under fasting conditions to evaluate bioequivalence.